TRDANasdaqPharmaceutical PreparationsFiscal year ends December 31
Entrada Therapeutics, Inc.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 5, 2026
$4.82+0.45 (+10.30%)
Close on Oct 19, 2026
- Market cap
- $203.51M
- P/E (TTM)
- –
- Dividend yield
- –
Entrada Therapeutics statistics
Financials through Jun 30, 2026, price as of Oct 19, 2026, median of Pharmaceutical Preparations companies for comparison
Valuation
| Measure | Entrada Therapeutics | Industry median |
|---|---|---|
| Market Cap | $187.68M | $164.85M |
| Enterprise Value | -$35.33M | $87.06M |
| PS Ratio | 40.05 | 3.60 |
| PB Ratio | 0.80 | 2.03 |
| P/TBV Ratio | 0.80 | 2.31 |
Enterprise value
| Measure | Entrada Therapeutics | Industry median |
|---|---|---|
| EV / Sales | -7.54 | 2.43 |
Income (trailing twelve months)
| Measure | Entrada Therapeutics | Industry median |
|---|---|---|
| Revenue | $4.69M | $57.94M |
| Operating Income | -$176.53M | -$21.44M |
| Net Income | -$165.78M | -$22.46M |
| EBITDA | -$176.53M | -$16.91M |
| EPS (Diluted) | -$3.96 | -$0.83 |
Margins
| Measure | Entrada Therapeutics | Industry median |
|---|---|---|
| Operating Margin | -3767.1% | -44.5% |
| Profit Margin | -3537.7% | -39.2% |
| EBITDA Margin | -3767.1% | -31.3% |
| FCF Margin | -2867.1% | -8.85% |
Returns
| Measure | Entrada Therapeutics | Industry median |
|---|---|---|
| Return on Equity (ROE) | -54.1% | -53.1% |
| Return on Assets (ROA) | -44.3% | -41.0% |
| Return on Invested Capital (ROIC) | -776.6% | -32.0% |
| Return on Capital Employed (ROCE) | -63.6% | -37.8% |
Growth
| Measure | Entrada Therapeutics | Industry median |
|---|---|---|
| Revenue Growth (YoY) | -94.1% | 6.01% |
Balance sheet
| Measure | Entrada Therapeutics | Industry median |
|---|---|---|
| Cash & Short-Term Investments | $223.00M | $62.42M |
| Net Cash (Debt) | $223.00M | $15.68M |
| Net Cash Per Share | $5.73 | $0.66 |
| Equity (Book Value) | $233.41M | $48.79M |
| Book Value Per Share | $5.99 | $1.36 |
| Tangible Book Value | $233.41M | $23.06M |
| Working Capital | $211.33M | $75.77M |
Financial position
| Measure | Entrada Therapeutics | Industry median |
|---|---|---|
| Current Ratio | 10.89 | 3.30 |
| Quick Ratio | 10.43 | 2.39 |
Cash flow (trailing twelve months)
| Measure | Entrada Therapeutics | Industry median |
|---|---|---|
| Operating Cash Flow | -$134.67M | -$12.35M |
| Capital Expenditures | $323.00K | -$1.06M |
| Free Cash Flow | -$134.35M | -$20.28M |
| FCF Per Share | -$3.45 | -$0.42 |
Efficiency
| Measure | Entrada Therapeutics | Industry median |
|---|---|---|
| Asset Turnover | 0.01 | 0.38 |
| Revenue Per Employee | $30.83K | $398.96K |
| Profits Per Employee | -$1.09M | -$703.34K |
| Employee Count | 152 | 74 |
Dividends and yields
| Measure | Entrada Therapeutics | Industry median |
|---|---|---|
| Earnings Yield | -88.3% | -22.7% |
| FCF Yield | -71.6% | -9.07% |
Shares
| Measure | Entrada Therapeutics | Industry median |
|---|---|---|
| Shares Outstanding | 38,936,700 | 58,179,650 |
| Shares Change (YoY) | 0.49% | 11.1% |
| Shares Change (QoQ) | 0.30% | 0.54% |
| Float | 33,187,600 | 49,173,100 |
| Shares Held by Insiders | 14.8% | 11.6% |
| Shares Held by Institutions | 75.6% | 59.4% |
Taxes
| Measure | Entrada Therapeutics | Industry median |
|---|---|---|
| Income Tax | $819.00K | $91.50K |
Scores
| Measure | Entrada Therapeutics | Industry median |
|---|---|---|
| Altman Z-Score | -1.03 | -0.24 |
| Piotroski F-Score | 2 | 4 |
Calculated by StockData from Entrada Therapeutics's SEC filings and the latest closing price. Hover a measure to see its formula. The grey column is the median of companies in the same industry group (two-digit SIC code); green or red marks a better or worse value than that median.